Cancer Gene Therapy Week articles from December 2004

Cancer Gene Therapy Week archives from December 2004

GAD 67KD antisense leaves colon cancer cells susceptible to cancer therapy.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- GAD 67KD antisense leaves colon cancer cells susceptible to cancer therapy. According to a study from South Korea, "in eukaryotes, glutamate decarboxylase (GAD) expression was found in brain,...

p21Waf1 gene transfer via gene gun technology limits esophageal cancer growth.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- p21Waf1 gene transfer via gene gun technology limits esophageal cancer growth. According to published research from Japan, "in our previous study, the proliferation rate of esophageal squamous cell...

Silenced heat shock protein 27 discourages prostate cancer progression.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- Silenced heat shock protein 27 discourages prostate cancer progression. According to recent research published in the journal Cancer Research, "heat shock protein 27 (Hsp27) is a chaperone...

Antibody-drug conjugate collaboration expanded.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- Seattle Genetics, Inc. (SGEN) announced that Genentech, Inc. (DNA) has agreed to pay a technology access fee of $1.6 million to designate additional antigen targets under the parties' existing...

STAG1 is a chief intermediary of the p53-dependent pro-apoptotic pathway.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- STAG1 is a chief intermediary of the p53-dependent pro-apoptotic pathway. "A mutant version of p53 (p53-121F), in which phenylalanine replaces the 121[superscript]st serine residue, can induce...

Nuclear localization of adenovirus E4orf4 protein correlates with cell death.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- Nuclear localization of adenovirus E4orf4 protein correlates with cell death. "The adenovirus E4orf4 protein induces p53-independent death of human cancer cells by a mechanism requiring interactions...

Scott Hawley named American Cancer Society research professor, awarded $300,000.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- Scott Hawley, PhD, investigator at the Stowers Institute for Medical Research, has been named an American Cancer Society (The Society) Research Professor. The designation carries an award of $300,000...

Type-1 innate and acquired immunity play crucial roles in tumor immunotherapy.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- Type-1 innate and acquired immunity play crucial roles in tumor immunotherapy. According to a study from Japan, "the discovery of a large array of tumor antigens has demonstrated that host...

Biopharma reports third quarter 2004 results, clinical achievements.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- Progenics Pharmaceuticals, Inc., (NASDAQ: PGNX) announced its results of operations for the third quarter ended September 30, 2004, and for the first 9 months of 2004. Revenues for the third...

Biopharmaceuticals company announces third quarter results, progress made.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- Keryx Biopharmaceuticals announced its financial results for the third quarter ended Sept. 30, 2004. At Sept. 30, 2004, Keryx announced cash, cash equivalents, interest receivable and investment...

Biotech company announces restructured agreement for cancer drug.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- Ligand Pharmaceuticals announced that it has restructured its agreement with Eli Lilly and Company with respect to the royalties payable to Lilly on sales of Ligand's marketed cancer drug Ontak...

Biotech establishes new business units for pain and oncology.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- Ligand Pharmaceuticals announced that it has established separate therapeutically focused business units for its pain and oncology products. Patrick M. Shea, formerly vice president of marketing,...

Molecular diagnostics company announces expansion of diagnostic pipeline.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- Third Wave Technologies Inc. (TWTI) provided new details about the expansion of the company's molecular diagnostic pipeline and issued preliminary guidance for 2005 clinical molecular diagnostic...

Fused cell vaccination and CpG oligodeoxynucleotides reject tumor recurrence.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- Fused cell vaccination and CpG oligodeoxynucleotides reject tumor recurrence. "Immunization with dendritic cells (DCs) using various antigen (Ag)-loading approaches has shown promising results in...

Skin cancer study using MedPulser Electroporation Therapy system begins.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- Genetronics Biomedical Corp. (GEB), a late-stage developer of oncology and other therapies using electroporation, has begun treating skin cancers in patients with primary and recurrent solid tumors...

Interleukin-15 transfection plus CD8+ T cells cause colon cancer rejection.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- Interleukin-15 transfection plus CD8+ T cells cause colon cancer rejection. "Although interleukin (IL)-15 augments innate and acquired immunities, IL-15 expression is controlled at the levels of...

Enzyme, inflammation have role in formation of vulnerable plaque, study shows.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- diaDexus announced findings from a new study that indicate a biological role for Lp-PLA2 (lipoprotein-associated phospholipase A2) in the formation of vulnerable plaque. The data were presented at the...

Primary endpoint achieved in phase 3 trial of genasense plus chemotherapy.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- Genta Incorporated (NASDAQ:GNTA) announced that the company's randomized phase 3 clinical trial of Genasense (oblimersen sodium) Injection in patients with relapsed or refractory chronic lymphocytic...

Affitech, Peregrine expand collaboration to develop new fully human antibodies.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- [lw2][pb2][uw2][vw2] (carol for Heather) Peregrine Pharmaceuticals Julie Marshall, +1-800-987-8256 Peregrine Pharmaceuticals, Inc., (NASDAQ:PPHM) and Affitech AS recently announced that they have...

Biopharma, consortium collaborate to treat brain cancer patients.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- [qw2][uw2][bb2][pb2] (carol for Heather) Peregrine Pharmaceuticals Julie Marshall, +1-800-987-8256, or info@hawkassociates.com Peregrine Pharmaceuticals, Inc., (NASDAQ:PPHM) has entered into a...

Companies combine technologies to search for cancer-fighting compounds.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- Tripos, Inc. (TRPS), and NovaScreen Biosciences Corporation have announced a collaboration to provide a drug discovery solution to Strida Pharma Inc. for its cancer therapeutics development program...

Companies introduce solid support product for manufacture of oligonucleotides.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- Nitto Denko Corporation, a polymer company, and Isis Pharmaceuticals, Inc. (ISIS), a RNA-based drug discovery and development company, have jointly developed a new solid support for the manufacture of...

DNA-based diagnostics company, biotech products provider announce partnership.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- Tm Bioscience Corporation (TMC), a diagnostics company in the commercial genetic testing market, has signed a development and supply agreement with Genzyme Corporation, a provider of biotechnology...

T-oligos trigger anticancer activity in melanoma cells.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- T-oligos trigger anticancer activity in melanoma cells. "Melanoma is the most fatal skin cancer, often highly resistant to chemotherapy. Here we show that treatment with an 11-base DNA...

Atomic structure of enzyme HSD-1 reported, use in diabetes treatment studied.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- Syrrx Inc., a structure-based drug discovery company, reported the publication of the atomic structure of human 11(beta)-hydroxysteroid dehydrogenase type-1 (HSD-1). HSD-1 inhibitors are being...

Indian pharmaceutical company launches new cancer diagnostic product.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- Indian pharmaceutical company J.B. Chemicals & Pharmaceuticals launched a high-tech diagnostic product used for angiographies, neurological diseases and diagnosis of cancer patients. The company...

New study addresses link between protein folding and factory construction.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- Part of a cellular mechanism that regulates the folding of new proteins into their proper shapes also includes a genetic response that enlarges the factory where both protein folding and packaging of...

Biopharm company focused on protein-deficiency disease reports Q3 results.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- Transkaryotic Therapies, Inc. (TKTX) announced its consolidated financial results for the 3 and 9 months ending September 30, 2004. Total sales of Replagal (agalsidase alfa), TKT's enzyme...

Ganite maker announces Q3 revenues of $1.4 million.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- Genta, Inc., (GNTA) announced financial results for the third quarter ended September 30, 2004. The company reported revenues of $1.4 million for the quarter and a net loss of $5.6 million or $0.07...

Pharmaceutical company reports third quarter revenue increase of 58%.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- Ligand Pharmaceuticals reported record net product sales for the third quarter ended Sept. 30, 2004, of $44.7 million, compared to $28.1 million the third quarter of 2003, an increase of 59% driven by...

Vaccine maker reports Q3 revenues of $69,000.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- Dendreon Corp. (DNDN) reported results for the quarter ended September 30, 2004. Revenues for the third quarter of 2004 were $69,000 compared to $1.8 million for the quarter ended September 30,...

Cytotoxic gene therapy is selective for human pancreatic cancer cells.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- Cytotoxic gene therapy is selective for human pancreatic cancer cells. According to a study from the United States, "the formation of a normal pancreas and the activation of insulin production are,...

Steroids and cholesterol enhance liposomal transfection of breast cancer cells.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- Steroids and cholesterol enhance liposomal transfection of breast cancer cells. "The efficiency of gene transfer is many times higher in viral than in liposomal transfection. One reason for this is...

DNA microarray of human sequence data available for life science researchers.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- NimbleGen Systems Inc. announced the availability of services using their new ENCODE microarray, designed in conjunction with the NHGRI-funded ENCODE (ENCyclopedia Of DNA Elements) Project Consortium....

U.S. Patent Office reissues patent for in vivo optical imaging for whole animals.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- Xenogen Corporation (XGEN), maker of advanced imaging technology to accelerate drug discovery and development, announced that the U.S. Patent and Trademark Office (USPTO) has reissued a patent on its...

Virginia Tech, research institute sign memorandum to conduct genomics research.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- The Institute for Genomic Research (TIGR) and Virginia Tech University have signed a memorandum of understanding, creating a new alliance that is expected to enhance TIGR's computational and...

Sindbis viral vectors detect and suppress advanced ovarian cancer xenografts.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- Sindbis viral vectors detect and suppress advanced ovarian cancer xenografts. "We studied the therapeutic value of Sindbis vectors for advanced metastatic ovarian cancer by using two highly...

Heat shock protein suicide gene-based tumor vaccine provokes antitumor activity.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- Heat shock protein suicide gene-based tumor vaccine provokes antitumor activity. According to a study from the United States, "tumor cells harbor a repertoire of unique, mutated antigens and shared...

Drug Web sites foster doctor and patient loyalty.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- According to a new survey of pharmaceutical companies with drug Web sites, doctors and patients are increasingly turning to the Internet for information on diseases such as cancer. Best Practices...

Company presents new immunomodulatory research at liver disease conference.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- Enzo Biochem, Inc., (ENZ), a biotechnology company, announced that its scientists presented five papers at the annual meeting of the American Association for the Study of Liver Disease, including three...

Data updates from phase 2 trial for metastatic melanoma drug presented.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- Vical Incorporated (VICL) reported safety and efficacy data from its high-dose phase 2 trial of Allovectin-7 in patients with metastatic melanoma, updating interim data reported in June 2004. ...

$10 million grant to evaluate lifestyle changes on breast cancer patients.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- Researchers at Kaiser Permanente announced the receipt of a $10 million grant to study whether lifestyle factors, such as diet, exercise and use of complementary and alternative medicine (CAM), impact...

Bcl-x[subscript]L knockdown strengthens TRAIL-induced death in prostate cancer cells.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- Bcl-x[subscript]L knockdown strengthens TRAIL-induced death in prostate cancer cells. "Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is cytotoxic to the majority of cancer cells...

Combined chemotherapy and immunotherapy generates tumor rejection.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- Combined chemotherapy and immunotherapy generates tumor rejection. According to published research from the Czech Republic, "Human papilloma virus 16 (HPV16) E6/E7 transformed mouse kidney cells...

Pharmaceutical company announces Phase I clinical trial for myeloma treatment.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- Kosan Biosciences announced that it has initiated a company-sponsored Phase Ib clinical trial to investigate KOS-953, Kosan's formulation of 17-AAG in combination with bortezomib (Velcade), a recently...

Focal adhesion kinase may be important therapeutic target.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- Focal adhesion kinase may be important therapeutic target in ovarian cancer, M.D. Anderson Cancer Center gynecologic oncologists say. According to A.K. Sood and colleagues, "Focal adhesion kinase...

Anticancer drug receives Candian patent.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- Lorus Therapeutics announced that its wholly owned subsidiary, GeneSense Technologies Inc., has been allowed a patent by the Canadian Patent Office entitled "Antitumor Antisense Sequences Directed...

U.S. NCI pediatric program established under contract to research hospital.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- The National Cancer Institute has announced the establishment of the Pediatric Preclinical Testing Program (PPTP), a program that will systematically test 10-15 agents or combinations of agents annually...

Gene therapy promoters should be inspected for their effects in local tissues.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- Gene therapy promoters should be inspected for their effects in local tissues. According to a study from Germany, "osteosarcoma (OS), a malignant bone neoplasia in childhood, has poor prognosis if...

Oncology-focused pharmaceutical names new heads of biologics, regulatory affairs.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- Spectrum Pharmaceuticals, Inc. (SPPI) has appointed Kolli Prasad, PhD, the former head of R&D for Shantha Biotechnics Pvt. Ltd., director of R&D, biologics. The company also appointed Paul Vilk,...

Biotech company obtains patent for key target involved in chronic pain.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- TransMolecular, Inc. announced the issuance of U.S. Patent No. 6,573,067 titled, "Nucleic acid encoding sodium channels in dorsal root ganglia." The current invention relates to a tetrodotoxin...

U.S. Patent issued for nucleic acid amplification device for biological research.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- Applied Biosystems (ABI), an Applera Corporation business, announced that the U.S. Patent & Trademark Office (USPTO) has granted Applera a fundamental patent pertaining to real-time PCR instrumentation...

U.S. patent granted for technology to detect nucleic acid sequences.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- NuGEN Technologies, Inc. announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 6,815,164, which is directed towards nucleic acid detection methods and probes for the detection...

Peripheral benzodiazepine receptor deregulation increases tumorigenicity.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- Peripheral benzodiazepine receptor deregulation increases tumorigenicity. "Peripheral benzodiazepine receptors (PBR), first described more than 20 years ago, have been attributed with many putative...

GST-MDA-7 fusion protein selects for and destroys cancer cells.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- GST-MDA-7 fusion protein selects for and destroys cancer cells. "The human melanoma differentiated associated-7/interleukin-24 (mda-7/IL-24) gene product is normally expressed in melanocytes and...

Bladder tumors respond to non-viral tumor necrosis factor-alpha gene transfer.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- Bladder tumors respond to non-viral tumor necrosis factor-alpha gene transfer. "Our aim was to evaluate the feasibility and efficacy of tumor necrosis factor-alpha (TNA-alpha) gene therapy in...

Anionic dendrimers convey antisense oligonucleotides to cancer cell targets.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- Anionic dendrimers convey antisense oligonucleotides to cancer cell targets. According to a study from Wales, "the optimal design of hybridization-competent antisense oligonucleotides (ODNs) coupled...

Porcine adenoviral vectors are effective vehicles for gene delivery.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- Porcine adenoviral vectors are effective vehicles for gene delivery. According to recent research from the United States, "preexisting immunity against human adenoviruses (HAd) limits the...

Biological and physical titers should be counted in virus-based gene therapy.
December 6, 2004... 2004 DEC 6 - (NewsRx.com & NewsRx.net) -- Biological and physical titers should be counted in virus-based gene therapy. According to a study from South Korea, "recombinant adeno-associated virus type 2 (rAAV2) viral vector, a non-pathogenic...

Autologous antitumor lymphocytes regress metastatic melanoma in cancer patients.
December 13, 2004... 2004 DEC 13 - (NewsRx.com & NewsRx.net) -- Autologous antitumor lymphocytes regress metastatic melanoma in cancer patients. According to scientists in the United States, "our recent clinical trials demonstrate that autologous cell transfer...

Thyroid transcription factor-1 boosts radioiodide retention in thyroid cancer.
December 13, 2004... 2004 DEC 13 - (NewsRx.com & NewsRx.net) -- Thyroid transcription factor-1 boosts radioiodide retention in thyroid cancer. According to a study from Japan, "loss of thyroid-specific gene expression and functions accompanied by loss of...

Therapy combining adenovirus vectors has increased transduction efficiency.
December 13, 2004... 2004 DEC 13 - (NewsRx.com & NewsRx.net) -- Therapy combining adenovirus vectors has increased transduction efficiency. "Low gene transfer rate is the most substantial hurdle in the practical application of gene therapy. One strategy to...

Ovine atadenovirus guides gene-directed enzyme prodrug therapy to cancer cells.
December 13, 2004... 2004 DEC 13 - (NewsRx.com & NewsRx.net) -- Ovine atadenovirus guides gene-directed enzyme prodrug therapy to cancer cells. According to a study from Australia, "gene-directed enzyme prodrug therapy (GDEPT), based on the Escherichia coli...

Protein to antigen fusion heightens the efficacy of DNA cancer vaccine.
December 13, 2004... 2004 DEC 13 - (NewsRx.com & NewsRx.net) -- Protein to antigen fusion heightens the efficacy of DNA cancer vaccine. "Delivery of antigens by injection of the encoding DNA allows access to multiple antigen-presenting pathways. Knowledge of...

'Handcuffing' and unpairing controls of P1 plasmid replication.
December 13, 2004... 2004 DEC 13 - (NewsRx.com & NewsRx.net) -- Researchers from the National Cancer Institute in the United States have shown that the a phenomena called 'handcuffing' and unpairing are important in controlling the replication of plasmid P1. ...

Drug-discovery alliance enters phase I clinical trials in cancer.
December 13, 2004... 2004 DEC 13 - (NewsRx.com & NewsRx.net) -- Isis Pharmaceuticals, Inc., (ISIS) announced that LY2181308, the first antisense drug to emerge from its drug-discovery alliance with Eli Lilly and Co. (LLY), has moved into phase I clinical trials in...

G-quartet oligonucleotides targeting Stat3 protein fight cancer growth.
December 13, 2004... 2004 DEC 13 - (NewsRx.com & NewsRx.net) -- G-quartet oligonucleotides targeting Stat3 protein fight cancer growth. "Stat3 is a signaling molecular and oncogene activated frequently in many human malignancies including the majority of...

Biotech company and university team up to develop therapeutics for unstable plaque.
December 13, 2004... 2004 DEC 13 - (NewsRx.com & NewsRx.net) -- Cancer and cardiovascular biotech company Kereos said that it has extended its research partnership with Washington University in St. Louis to continue ongoing development of unique therapeutics that...

Novel DNA cross-linking agent has potent/selective cytotoxicity in CLL B cells.
December 13, 2004... 2004 DEC 13 - (NewsRx.com & NewsRx.net) -- A novel DNA cross-linking agent has potent and selective cytotoxicity in chronic lymphocytic leukemia B cells. "SJG-136 (NSC 694501) is a novel DNA cross-linking agent that binds in a...

Pharmaceutical company announces new research collaboration.
December 13, 2004... 2004 DEC 13 - (NewsRx.com & NewsRx.net) -- Locus Pharmaceuticals, Inc., announced the initiation of a multi-stage research collaboration with Dow AgroSciences LLC, a subsidiary of The Dow Chemical Company, focused on agrochemicals and...

Biotech raises $410,000 in non-brokered private placement.
December 13, 2004... 2004 DEC 13 - (NewsRx.com & NewsRx.net) -- Kyto Biopharma announced completion of a non-brokered private placement of 500,000 shares at a price of $.50 per share for proceeds of $250,000. Kyto also said that it converted a debt of $160,000...

DNA-based diagnostics company reports third quarter results.
December 13, 2004... 2004 DEC 13 - (NewsRx.com & NewsRx.net) -- Tm Bioscience Corporation (TMC), a DNA-based diagnostic testing company, announced its financial and operational results for the third quarter ended September 30, 2004. The company also announced...

NK4 staunches gastric cancer-related peritoneal metastasis in mice.
December 13, 2004... 2004 DEC 13 - (NewsRx.com & NewsRx.net) -- NK4 staunches gastric cancer-related peritoneal metastasis in mice. According to published research from Japan, "the competitive inhibitory effects of NK4 (a specific hepatocyte growth factor...

Canadian genetics company receives certification to updated regulatory standard.
December 13, 2004... 2004 DEC 13 - (NewsRx.com & NewsRx.net) -- Tm Bioscience Corporation (TMC), Toronto, Ontario, a commercial genetic testing company, announced that its Quality Management System, which covers all aspects of the company's operations, meets the...

Kinase knockdown vectors now include multigenics.
December 13, 2004... 2004 DEC 13 - (NewsRx.com & NewsRx.net) -- Genomatix Corporation announced the expansion of its kinase knockdown solutions to include custom multigenic vectors. According to the company, kinase knockdown vectors can now be ordered with...

Local blockade of negative stimulatory molecules augments antitumor cytokines.
December 13, 2004... 2004 DEC 13 - (NewsRx.com & NewsRx.net) -- Local blockade of negative stimulatory molecules augments antitumor cytokines. "The negative signal provided by interactions of programmed death-1 (PD-1) and its ligands, costimulatory molecules...

Webware for analysis and reporting chromosomal data from array CGH launched.
December 13, 2004... 2004 DEC 13 - (NewsRx.com & NewsRx.net) -- Spectral Genomics, Inc. announced the introduction of its web-enabled SpectralWare, a software suite for the analysis and reporting of data from array comparative genomic hybridization (CGH). The...

Combined gene therapy and cancer immunotherapy attack glioma in murine models.
December 13, 2004... 2004 DEC 13 - (NewsRx.com & NewsRx.net) -- Combined gene therapy and cancer immunotherapy attack glioma in murine models. "Effective presentation of tumor antigens by dendritic cells (DCs) is considered to be essential for the induction of...

Biotech company announces commercial supply agreement for cancer treatment.
December 13, 2004... 2004 DEC 13 - (NewsRx.com & NewsRx.net) -- Lorus Therapeutics Inc. announced the signing of a commercial supply agreement with Diagnostic Chemicals Limited operating as BioVectra dcl for the commercial manufacture of Virulizin. Lorus said...

Biotech company announces initiation of Phase II trial for cancer treatment.
December 13, 2004... 2004 DEC 13 - (NewsRx.com & NewsRx.net) -- Lorus Therapeutics Inc. announced the initiation of a clinical trial of its antisense drug, GTI-2040, in combination with docetaxel and prednisone in hormone refractory prostate cancer (HRPC) at...

Government, academic, medical collaboration launches Spanish cancer program.
December 13, 2004... 2004 DEC 13 - (NewsRx.com & NewsRx.net) -- In a move that promises to transform cancer research and patient care for the benefit of all citizens of Spain, an unprecedented group of government, scientific and medical partners announced the...

New census shows growth in PET/CT installations.
December 13, 2004... 2004 DEC 13 - (NewsRx.com & NewsRx.net) -- An estimated 706,100 clinical PET patient studies were performed in the United States in 2003, according to a report released by IMV Medical Information Division. These PET studies were performed...

Coding sequence determined for orthologs of prostate cancer susceptibility gene.
December 13, 2004... 2004 DEC 13 - (NewsRx.com & NewsRx.net) -- The coding sequence was determined for orthologs of the prostate cancer susceptibility gene. "The human ELAC2 gene was the first candidate prostate cancer susceptibility gene identified by linkage...

HIF1A gene polymorphisms associated with renal cell carcinoma phenotype.
December 13, 2004... 2004 DEC 13 - (NewsRx.com & NewsRx.net) -- Hypoxia inducible factor 1 alpha gene polymorphisms are associated with the renal cell carcinoma phenotype. "Hypoxia inducible factor 1 (HIF-1) is a key regulator of the genes involved in the...